However, the efficacy of combining ADCs with PD‐1/PD‐L1 inhibitors still requires validation through larger clinical studies, with ongoing trials evaluating ADCs targeting HER2, claudin18.2, or Trop2 in combination with PD‐1 inhibitors for GC treatment. This evidence concerns the gene ERBB2 and gastric cancer.